Drug combo for HER2-negative breast cancer brain metastasis
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two drugs (adebrelimab and apatinib) plus chemotherapy for women with HER2-negative breast cancer that has spread to the brain. It aims to see if this treatment can help shrink or control brain tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and at least 18 years old.
- Your breast cancer is HER2-negative (a certain protein tested low or absent).
- You have brain metastases that are new or have grown after previous treatment.
- Your general health is good enough to be up and about for at least half the day (performance status 0–2).
- You can swallow pills and your major organs (heart, liver, kidneys) are working fairly well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a PD-L1 inhibitor with a low-dose chemotherapy regimen and either immediate or delayed radiation therapy for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this approach helps shrink brain tumors and improve outcomes.
This trial tests a new combination of targeted drugs for HER2-positive breast cancer that has spread to the brain. You might be able to join if you have brain metastases and are either newly diagnosed or have had prior brain radiation.
This trial tests two new drugs, SHR-A1811 and THPy, for women with HER2-positive advanced breast cancer that has spread to the brain. It aims to see if this combination can shrink brain tumors and improve outcomes for patients who have not yet had systemic treatment for advanced disease.
This Phase 2 study tests SHR-A1811 in people with HER2-positive (or HER2-low) advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and control the cancer in the brain, especially when there was no need for urgent local treatment like radiation or surgery.
This study is testing a new targeted therapy for people with HER2-positive breast cancer that has spread to the brain. It aims to see if the drug can help shrink brain tumors and improve outcomes for two groups: those with cancer in the fluid around the brain and those without.
This trial tests whether a combination of three drugs (SHR-A1811, pyrotinib, and bevacizumab) can help people with advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and stop them from growing.
Hear when a new HER2-negative Breast Cancer Brain Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.